together we can do it 

PARTNERS AND INVESTORS

FundaMental Pharma has completed a Seed Financing round to fund development of its N/T interface inhibitors in its starting indication of Amyotrophic Lateral Sclerosis.

Fundamental Pharma is open to partner on its breakthrough approach for neurodegenerative diseases.
For additional information, please contact us.